802 Table 1 :Patient Demographics Characteristics (N= 412) Median Age in Years (IQR) 55.1 (48, 66) Female 153 (37%) Race White/Caucasian 367 (89%) Black/African American 29 (7%) Other 12 (3%) Bilateral Lung Tx 309 (75%) Post-Tx Delayed Gastric Emptying (DGE) 236 (57.3%) Pre-Tx SGE (subgroup) 96 (22.6%) Pre-Op DGE 12 (13%) Post-Op DGE 61 (64%) %With Newly dx DGE 49 (51%) Table 2: % Reduction in Gastric Emptying at Various Time Points after Transplant Study Time Pre-Tx % Mean Gastric Emptying (SD) Post-Tx % Mean Gastric Emptying (SD) % Mean Reduction (SD) P-Value 60 39.6 (18.5) 29.4 (21.9) 10.1 (28.1) 0.001 120 71.3 (21.6) 45.2 (27.1) 26.0 (36.3) <0.001 240 92.2 (11.9) 67.2 (29.8) 25.3 (34.4) <0.001 Abstract# C2011 De Novo Donor Specific Antibodies in Renal and Lung Transplantation:A Comparison of Incidence, Risk Factors, and Outcomes. R. Knight, 1 J. DeVos, 2 A. Islam, 1 S. Patel, 2 S. Jyothula, 3 N. Sinha, 3 G. Land, 4 A. Gaber. 1 1 Surgery, Houston Methodist Hospital, Houston, TX; 2 Pharmacy, Houston Methodist Hospital, Houston, TX; 3 Medicine, Houston Methodist Hospital, Houston, TX; 4 Pathology, Houston Methodist Hospital, Houston, TX. Background: Development of de novo donor specific anti-HLA antibodies (dnDSA) is associated with poor long-term graft survival. This study compared the incidence, risk factors, and outcomes of dnDSA in renal and lung transplant populations. Methods: At a single center, 608 renal transplant recipients from 7/2007–7/2011 and 437 lung transplant recipients from 1/2009-7/2013, were monitored for dnDSA at >5 time-points within the first year post-transplant and every 6 months thereafter. 215 transplants were excluded because of pre-transplant DSA, 0-HLA mismatch, or follow-up < 1 month. Results: With median follow-ups of 31 and 16 months respectively, 24% (120/503) of renal vs. 23% (76/327) of lung transplant recipients developed dnDSA (p=NS). Class II dnDSA occurred in 66% of renal vs. 48% of lung recipients (p=NS) and dnDSA was persistent ( ≥2 positive time points) in 65% of renal vs. 67% of lung recipients (p=NS). The median time to onset of dnDSA was 6 months and 4 months respectively for renal and lung recipients. Using multivariate analysis, independent risk factors for dnDSA in renal recipients were African American race (OR: 2.37, p<0.01), increasing HLA mismatch (OR:1.19,p<0.01), and a kidney pancreas transplant (OR:2.44, p=0.02). Similarly, in lung recipients, risk factors were non-Caucasian race (OR:2.11, p=0.01), HLA-DQ mismatch (OR:2.15, p=0.01), and increased lung allocation score (OR:1.18, p=0.05). With longer follow-up in renal recipients, there was an increased rate of acute rejection (35 vs. 10%, p<0.01) and graft loss (11 vs. 2%, p<0.01) in those with dnDSA compared to those without dnDSA. In the lung transplant cohort, the rate of acute rejection (36 vs. 39%, p=ns) and graft loss (5 vs. 5%) was equivalent between the dnDSA and no DSA groups respectively. Conclusions: The incidence, time of onset, type, and persistence of dnDSA was equivalent between renal and lung transplant recipients. Additionally, independent risk factors for development of dnDSA were similar between groups. The detrimental impact of dnDSA noted in the renal recipients was not observed during the shorter follow-up period of the lung recipients. DISCLOSURES: Knight, R.: Speaker’s Bureau, Novartis. Abstract# C2012 Long Term Survival of Lung Transplant Recipients After Implementation of Lung Allocation Score. J. Mooney, 1 B. Maxwell, 2 J. Levitt, 1 B. Goldstein, 1 M. Nicolls, 1 D. Weill, 1 G. Dhillon. 1 1 Stanford University, Stanford, CA; 2 Johns Hopkins School of Medicine, Baltimore. Purpose: The implementation of lung allocation score (LAS) in 2005 has not impacted one-year survival, though post one year survival has not been assessed. Methods: The survival of all lung transplants available in the Scientific Registry of Transplant Recipients between 1/1, 1995 and 6/1, 2010 was assessed. We compared three cohorts: 2005-10 (post LAS); 2001-05 (pre LAS); and 1995-2000 (historical control). Overall survival rates and one-year conditional survival were compared by Kaplan-Meier statistics and marginal hazard ratios for death. Results: 17,146 adults received lung transplant during this time period. The patients in post LAS cohort were older, sicker, and more likely to have pulmonary fibrosis. Historical Controls Pre LAS Post Las Number 5081 4628 7437 Age, Median & IQR 51 (40, 58) 55 (44, 60) 57 (47, 63) ICU 192 (3.8%) 163 (3.5%) 603 (8.2%) Hospitalized 300 (6.0%) 207 (4.5%) 576 (7.7%) Not Hospitalized 4543 (90.2%) 4257 (92%) 6258 (84.1%) On ventilator 153 (3 %) 122 (2.6%) 449 (6%) Obstructive Lung Diseases 2607 (51%) 2311 (50%) 2341 (33%) Pulmonary Vascular Diseases 290 (6%) 182 (4%) 229 (3%) Cystic Fibrosis & related conditions 861(17%) 674 (15%) 935 (13%) Restrictive Lung Diseases 1133 (22%) 1411 (30%) 3778 (51%) The one-year survival was similar between pre- and post-LAS cohorts (82.1% vs 83.1%); and significantly better than the historical control (75%). The one-year conditional survival of post-LAS cohort was worse than pre-LAS (MHR 1.12, IQR 1.02-1.23) cohort and similar to historic control (MHR 0.98, IQR 0.90-1.08) Conclusion:Even though implementation of LAS has not affected one-year survival after lung transplantation, the decreased one-year conditional survival suggests a potential negative long-term effect of the LAS. Abstract# C2013 Outcomes of Single Versus Double Lung Transplant Including High Risk Donors in Pulmonary Fibrosis. D. Ren, 1 L. Blau, 1 T. Kaleekal, 2 S. Jyothula, 2 E. Suarez, 1 M. Loebe, 1 B. Bruckner. 1 1 DeBakey Heart and Vascular Surgery Department, Houston Methodist Hospital, Houston, TX; 2 Division of Pulmonary Medicine, Department of Medicine, Houston Methodist Hospital, Houston, TX. Purpose. Which procedure is better when comparing single lung versus double lung transplantation in patients with idiopathic pulmonary fibrosis (IPF)? Should recipient age impact decisions on transplant type? Will there be a survival difference © The Authors. Compilation © The American Society of Transplant Surgeons, The Transplantation Society and the American Society of Transplantation